Hanna Hedman

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
An analysis was performed on a data set of 157 orphan designated medicines with an outcome for marketing authorisation application (MAA) between 2000 and 2013. The intention was to understand the factors associated with marketing authorisation success, the challenges developers face regarding orphan medicine development, and how scientific advice (SA) is(More)
Drawing on the author's personal experience both as a renal patient and involvement with patient organisations, this paper identifies issues related to patient choice and compliance with renal replacement therapy. The author emphasises the importance of effective patient education and describes the contribution that patient organisations can make in(More)
  • 1